glp-1 obesity drugs updates today Variable weight-loss and cardiovascular benefits were seen with in a systematic review and network meta-analysis, but effects on quality of life were less clear. https://www.medpagetoday.com/primarycare/obesity /122142 GLP-1 Pipeline Update: February 2025

doi: 10.1161/CIRCULATIONAHA.113.005081 34 CastanedaAMDutra-RufatoAJuarezMJGrosembacherLGonzalez-TorresHMussoCG

Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease

As weight is lost, the body adapts (metabolically) and requires fewer calories to support a lower weight, Dawkins says

About 80% of people taking these medications will experience one or more of these undesirable digestive symptoms, predictably more so at higher doses

Saxenda isnt known to interact with alcohol

Pre-clinical and mechanistic studies on cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders (Supplementary Table 5